Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prostate cancer

Table 1 Clinical characteristics of the feasibility cohort

Unique ID	Age (years)	PSA (ng/mL)	Prior therapies*	Events on FACS	Confirmed CTCs by IF
11001	61	1077	L, B, K, O, D, M	1700	22
11002	80	787	L, D+/-Da	294	17
11003	88	124.3	L, B	94	0
11004	76	201.3	L, T, B, N, D	0	0
11005	80	741	L, F, D, M, E vs pl	4	1
11006	58	168.1	L, B, D	0	0
11007	62	34.24	L, B, D, E	3	0
11008	63	1971	L, B, D, M + I	751	17
11009	62	68.45	L, B, D, M	60	4
11010	79	2229	L, B, D, M, Ctx	62	0
11011	71	218.9	L, B, D+/- Af, E	345	23
11012	70	1425	L	290	25
11013	72	50.15	L, B, F, K, O	431	22
11014	81	25.5	L, B, O, T	237	10
11015	80	70.8	L, B, Di, D, S	86	3

*Prior therapies: A = aflibercept, B = bicalutamide, C = cyclophosphamide, Ci = cixutumumab, D = docetaxel, Da = dasatinib, Di = diethylstilbestrol, E = enzalutamide, F = flutamide, K = ketoconazole, L = LHRH agonist, M = mitoxantrone, N = nilutamide, O = orteronel, P = placebo, S = samarium lexidronam, T = tasquinimod.